Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Revelation Biosciences, Inc. Warrant (REVBW)

Pharmaceutical Preparations

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

4660 LAJOLLA VILLAGE DRIVE, SUITE 100
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/11/2022

Market Cap

1,594,318

Shares Outstanding

6,300,000

Weighted SO

N/A

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

REVB --.--%

SABSW --.--%

SRZNW --.--%

JSPRW --.--%

ISPOW --.--%

Beta

0.2160

Last Div

0.0000

Range

0.0099-0.0118

Chg

0.0008

Avg Vol

N/A

Mkt Cap

1594318

Exch

NASDAQ

Country

US

Phone

917 622 5800

DCF Diff

-6.3851

DCF

9.7451

Div Yield

0.0000

P/S

38.0734

EV Multiple

1.1092

P/FV

1.2482

Div Yield %

0.0000

P/E

-0.0895

PEG

-0.0009

Payout

0.0000

Current Ratio

1.0961

Quick Ratio

1.0961

Cash Ratio

1.0848

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

17983.6536

CCC

-17983.6536

Gross Margin

0.3079

Op Margin

-253.5883

Pretax Margin

-423.2323

Net Margin

-423.2323

Eff Tax Rate

0.0058

ROA

-1.2961

ROE

-2.4391

ROCE

-8.3551

NI/EBT

1.0000

EBT/EBIT

1.6690

EBIT/Rev

-253.5883

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-1.2249

CF/Debt

0.0000

Equity Multi

10.7588

Rec Turnover

0.0000

Pay Turnover

0.0203

Inv Turnover

0.0000

FA Turnover

0.5309

Asset Turnover

0.0031

OCF/Share

-5.5259

FCF/Share

-5.5376

Cash/Share

7.3831

OCF/Sales

-240.4899

FCF/OCF

1.0021

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

-471.3210

Div&CapEx Cov

-471.3210

P/BV

1.2482

P/B

1.2482

P/S

38.0734

P/E

-0.0895

P/FCF

-0.1580

P/OCF

-0.1575

P/CF

-0.1575

PEG

-0.0009

P/S

38.0734

EV Multiple

1.1092

P/FV

1.2482

DPS

0.0000

Latest Headlines (EST)

No Headlines Found

Revenue Product Segmentation